GS7.F - GlaxoSmithKline plc

Frankfurt - Frankfurt Delayed price. Currency in EUR
17.36
-0.00 (-0.01%)
As of 11:20AM CEST. Market open.
Stock chart is not supported by your current browser
Previous close17.36
Open17.35
Bid17.37 x 110000
Ask17.40 x 110000
Day's range17.34 - 17.37
52-week range16.21 - 19.90
Volume2,150
Avg. volume7,629
Market cap81.42B
BetaN/A
PE ratio (TTM)34.51
EPS (TTM)N/A
Earnings dateN/A
Forward Dividend & YieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GSK wins U.S. shingles vaccine approval, UK nod for gene therapy
    Reuters1 hour ago

    GSK wins U.S. shingles vaccine approval, UK nod for gene therapy

    GlaxoSmithKline (GSK.L) has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called "bubble boy" disease -- a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe.

  • Reuters - UK Focus1 hour ago

    GSK wins U.S. shingles vaccine approval, UK nod for gene therapy

    LONDON, Oct (Shenzhen: 000069.SZ - news) 23 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called "bubble boy" disease -- a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe.

  • Reuters10 hours ago

    Britain backs GSK's gene therapy for 'bubble boy' syndrome

    Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment. Britain's National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem cell transplant therapy.

  • Reuters - UK Focus11 hours ago

    Britain backs GSK's gene therapy for "bubble boy" syndrome

    GlaxoSmithKline's gene therapy for the so-called "bubble boy" disease was approved by Britain's healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros . Gene therapy is designed ...

  • FDA approves better vaccine against painful shingles virus
    Associated Press2 days ago

    FDA approves better vaccine against painful shingles virus

    U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus.

  • Reuters2 days ago

    GlaxoSmithKline adult shingles vaccine wins U.S. approval

    Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co (MRK.N). The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data. Glaxo said the U.S. Centers for Disease Control and Prevention's advisory committee on immunization practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday.

  • Reuters - UK Focus2 days ago

    GlaxoSmithKline adult shingles vaccine wins U.S. approval

    Oct (Shenzhen: 000069.SZ - news) 20 (Reuters) - The U.S. Food and Drug Administration approved GlaxoSmithKline (Other OTC: GLAXF - news) 's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday. Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck (Jakarta: 28586808.JK - news) & Co. The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters (Dusseldorf: TOC.DU - news) data.

  • Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?
    Zacks3 days ago

    Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

    The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

  • 3 High-Yield Pharmaceutical Stocks
    Motley Fool3 days ago

    3 High-Yield Pharmaceutical Stocks

    High-yield pharma stocks are rare, but these three offer comparatively fat payouts.

  • China Biotech Promise Struggles to Keep Foreign Innovators
    Bloomberg4 days ago

    China Biotech Promise Struggles to Keep Foreign Innovators

    As money rushes into China’s fledgling biotechnology sector, Eli Lilly & Co. and other foreign drugmakers are scaling back.

  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacks5 days ago

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • Market Realist5 days ago

    What GlaxoSmithKline’s 3Q17 Performance Tells Us

    GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

  • Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
    Zacks6 days ago

    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

  • Reuters10 days ago

    GlaxoSmithKline's shingles vaccine gets approval in Canada

    (Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...

  • The Wall Street Journal11 days ago

    [$$] Ebola Vaccines Show Promise in New Study

    The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...

  • May to consult business leaders on Brexit
    Reuters14 days ago

    May to consult business leaders on Brexit

    Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.

  • Fool.co.uk16 days ago

    GlaxoSmithKline plc is one of 10 top stocks for a Footsie starter portfolio

    G A Chester's quarterly review of 10 FTSE 100 (INDEXFTSE:UKX) industry giants, including GlaxoSmithKline plc (LON:GSK).

  • Market Realist18 days ago

    Changes in GlaxoSmithKline’s Valuation

    As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.

  • Market Realist18 days ago

    Performance of GlaxoSmithKline’s Consumer Healthcare Segment

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.

  • Market Realist18 days ago

    Quarterly Performance of GlaxoSmithKline’s Vaccines Segment

    The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16.

  • Market Realist19 days ago

    Quarterly Performance for GlaxoSmithKline’s HIV Business

    HIV products reported a 29.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by the strong performances of Tivicay and Triumeq.

  • Market Realist19 days ago

    GlaxoSmithKline’s Pharmaceuticals Segment in 2Q17

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment reported a 3.0% rise in revenues at constant exchange rates and a 9.0% positive impact of foreign exchange in 2Q17.

  • Market Realist20 days ago

    GlaxoSmithKline’s Quarterly Revenues

    GlaxoSmithKline (GSK) reported a 12.0% rise in revenues to 7.3 billion pounds in 2Q17 compared to 6.5 billion pounds in 2Q16.

  • Market Realist20 days ago

    GlaxoSmithKline’s Recent 3Q17 Developments

    On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies.

  • Reuters21 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee. The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes